(R)-2'-(((tert-butoxycarbonyl)amino)methyl)-4-methyl-4,5-dihydro-[2,4'-bithiazole]-4-carboxylic acid | 1033814-13-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-2'-(((tert-butoxycarbonyl)amino)methyl)-4-methyl-4,5-dihydro-[2,4'-bithiazole]-4-carboxylic acid
• 英文别名: (R)-2-(2-((tert-butoxycarbonylamino)methyl)thiazol-4-yl)-4-methyl-4,5-dihydrothiazole-4-carboxylic acid；(4R)-4-methyl-2-[2-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]-1,3-thiazol-4-yl]-5H-1,3-thiazole-4-carboxylic acid
• CAS: 1033814-13-9
• 化学式: C₁₄H₁₉N₃O₄S₂
• 分子量: 357.455
• InChiKey: CKELNQMVLKMSOY-AWEZNQCLSA-N

物化性质

• 熔点：
  75-80 °C(Solv: ethyl acetate (141-78-6); ligroine (8032-32-4))
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  154
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (R)-2'-(((tert-butoxycarbonyl)amino)methyl)-4-methyl-4,5-dihydro-[2,4'-bithiazole]-4-carboxylic acid 在 盐酸 、 4-二甲氨基吡啶 、 2,4,6-三氯苯甲酰氯 、 二乙胺 、 N,N-二异丙基乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 6.41h， 生成 (4R)-2-[2-[[[(E,3S)-3-[(2S)-2-amino-3-methylbutanoyl]oxy-7-tritylsulfanylhept-4-enoyl]amino]methyl]-1,3-thiazol-4-yl]-4-methyl-5H-1,3-thiazole-4-carboxylic acid
  参考文献：
  名称：

  Largazole and Analogues with Modified Metal-Binding Motifs Targeting Histone Deacetylases: Synthesis and Biological Evaluation

  摘要：

  The histone deacetylase inhibitor largazole 1 was synthesized by a convergent approach that involved several efficient and high yielding single pot multistep protocols. Initial attempts using tert-butyl as thiol protecting group proved problematic, and synthesis was accomplished by switching to the trityl protecting group. This synthetic protocol provides a convenient approach to many new largazole analogues. Three side chain analogues with multiple heteroatoms for chelation with Zn2+ were synthesized, and their biological activities were evaluated. They were less potent than largazole 1 in growth inhibition of HCT116 colon carcinoma cell line and in inducing increases in global H3 acetylation. Largazole 1 and the three side chain analogues had no effect on HDAC6, as indicated by the lack of increased acetylation of alpha-tubulin.

  DOI：

  10.1021/jm200432a
• 作为产物：
  描述：

  methyl 2-(tert-butoxycarbonylaminomethyl)thiazole-4-carboxylate 在 碳酸氢钠 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸酐 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 2.17h， 生成 (R)-2'-(((tert-butoxycarbonyl)amino)methyl)-4-methyl-4,5-dihydro-[2,4'-bithiazole]-4-carboxylic acid
  参考文献：
  名称：

  Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability

  摘要：

  The total synthesis of largazole and four analogues is reported. All analogues were nanomolar HDAC inhibitors. The antiproliferative activity is driven by lipophilicity and cell permeability. In murine liver homogenates, largazole is rapidly metabolized (half-life <= 5 min) to the thiol which has a half-life of 51 min. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.02.024

文献信息

• Process Development and Scale-up Total Synthesis of Largazole, a Potent Class I Histone Deacetylase Inhibitor
  作者：Qi-Yin Chen、Pravin R. Chaturvedi、Hendrik Luesch

  DOI：10.1021/acs.oprd.7b00352

  日期：2018.2.16

  scale-up total synthesis of largazole, a potent class I selective histone deacetylase (HDAC) inhibitor, a potential anticancer agent and also useful for the treatment of other disorders where transcriptional reprogramming might be beneficial. The synthetic route and conditions for each fragment and final product were modified and optimized to make them suitable for larger-scale synthesis. With the

  在此，我们描述了拉格唑放大全合成工艺的研究和开发，拉格唑是一种有效的 I 类选择性组蛋白脱乙酰酶 (HDAC) 抑制剂，是一种潜在的抗癌药物，也可用于治疗转录重编程可能影响的其他疾病。有利。对每个片段和最终产物的合成路线和条件进行了修改和优化，使其适合大规模合成。通过我们开发的工艺，可以以良好到优异的产率合成数百克的每个片段和十克的最终产品拉格唑。根据最长序列，经过八个步骤，最终目标拉格唑的总产率为 21%，HPLC 纯度超过 95%。
• Radical-Mediated Thiol-Ene Strategy: Photoactivation of Thiol-Containing Drugs in Cancer Cells
  作者：Shuang Sun、Bruno L. Oliveira、Gonzalo Jiménez-Osés、Gonçalo J. L. Bernardes

  DOI：10.1002/anie.201811338

  日期：2018.11.26

  Photoactivated drugs provide an opportunity to improve efficacy alongside reducing side-effects in the treatment of severe diseases such as cancer. Described herein is a photoactivation decaging method of isobutylene-caged thiols through a UV-initiated thiol-ene reaction. The method was demonstrated with an isobutylene-caged cysteine, cyclic disulfide-peptide, and thiol-containing drug, all of which

  光活化药物为治疗癌症等严重疾病提供了提高疗效并减少副作用的机会。本文描述了通过UV引发的硫醇-烯反应对异丁烯笼蔽的硫醇进行光活化解笼的方法。该方法通过异丁烯笼住的半胱氨酸、环状二硫肽和含硫醇的药物进行了论证，所有这些药物在硫醇源和光引发剂存在下，在温和的紫外线照射下都能快速有效地释放。重要的是，研究表明组蛋白脱乙酰酶抑制剂拉格唑的活性在缝合时可以关闭，但在用非光毒性光照射时在癌细胞内选择性地打开。
• Method for preparing largazole analogs and uses thereof
  申请人：Williams Robert M.

  公开号：US20100029731A1

  公开（公告）日：2010-02-04

  Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.

  本文描述了类似largazole的类似物。此外，还描述了使用largazole和largazole类似物治疗癌症和血液疾病的方法，以及包含它们的药物组合物。同样描述了制备largazole类似物的方法。
• Enantioselective Total Synthesis of (+)-Largazole, a Potent Inhibitor of Histone Deacetylase
  作者：Arun K. Ghosh、Sarang Kulkarni

  DOI：10.1021/ol8014623

  日期：2008.9.1

  An enantioselective total synthesis of the cytotoxic natural product (+)-largazole (1) is described. It is a potent histone deacetylase inhibitor. Our synthesis is convergent and involves the assembly of thiazole 3-derived carboxylic acid with amino ester 4 followed by cycloamidation of the corresponding amino acid. The synthesis features an efficient cross-metathesis, an enzymatic kinetic resolution

  描述了细胞毒性天然产物 (+)-拉格唑 (1) 的对映选择性全合成。它是一种有效的组蛋白脱乙酰酶抑制剂。我们的合成是收敛的，涉及噻唑 3 衍生的羧酸与氨基酯 4 的组装，然后是相应氨基酸的环酰胺化。该合成具有高效的交叉复分解、β-羟基酯的酶动力学拆分、选择性去除 Boc 保护基团、HATU/HOAt 促进的环酰胺化反应以及对敏感硫酯官能团的合成操作。
• A fluorine scan on the Zn2+-binding thiolate side chain of HDAC inhibitor largazole: Synthesis, biological evaluation, and molecular modeling
  作者：Bingbing Zhang、Jiami Liu、Dingding Gao、Xiaolin Yu、Jinlei Wang、Xinsheng Lei

  DOI：10.1016/j.ejmech.2019.111672

  日期：2019.11

  comparable or enhanced activity and selectivity in enzymatic assays. Two of the sulfhydryl esters have also exhibited excellent inhibitory activity in cellular assays with a few selected cell lines. The C19-fluorinated analogue has been further studied by immunoblot analysis, confirming that it is a potent selective class I HDAC inhibitor and supporting that the potent cellular antiproliferative activity is

  基于常见单位在含硫天然组蛋白脱乙酰基酶（HDACs）抑制剂家族中的独特作用，我们选择了拉加唑作为这些抑制剂的实例，并采用“氟扫描”策略来修饰该常见单位。因此，已经设计，合成和评估了一组氟代largazole类似物，并进行了酶法和细胞分析。初步结果表明，在单元的各个位置引入氟对HDAC的活性和选择性有重要影响。与文献中报道的经常导致活性显着降低或完全丧失的其他修饰不同，这些氟代硫醇中的大多数在酶法测定中均显示出可比或增强的活性和选择性。巯基酯中的两种在一些选定的细胞系的细胞测定中也表现出优异的抑制活性。通过免疫印迹分析对C19氟化类似物进行了进一步研究，证实了它是有效的选择性I类HDAC抑制剂，并支持有效的细胞抗增殖活性是由于HDAC抑制所致。分子对接研究表明，在C19位置引入氟不会改变原始的相互作用，但可能会改变结合构象，从而显着改善活性。证实它是有效的选择性I类HDAC抑制剂，并支持有效